AbbVie is making a decisive move to strengthen its manufacturing footprint in the United States, announcing a $1.4 billion investment to build a major production campus in Durham, North Carolina.
The 185-acre site, located بالقرب de Research Triangle Park, will support the production of medicines across immunology, neuroscience and oncology — three of the company’s core therapeutic areas. Once completed, it will represent AbbVie’s largest single-site investment to date.
Construction is set to begin in 2026, with full completion expected by the end of 2028. Over the next four years, the project is expected to generate 734 jobs, spanning engineering, scientific research, production operations and laboratory functions.
At the heart of the facility will be small-volume parenteral (SVP) manufacturing — sterile injectable treatments such as vials, cartridges and prefilled syringes, typically under 100 millilitres. These formats are critical for modern therapies requiring precision dosing and high-quality sterile environments.
The first phase will include manufacturing units, laboratories, warehousing infrastructure, administrative offices and employee wellness facilities. Artificial intelligence will also be integrated into production processes, reflecting a broader shift toward smarter, more automated pharmaceutical manufacturing.
AbbVie positions the Durham campus as a future centre of excellence for SVP manufacturing in the US, with global distribution capabilities. The location was selected not only for expansion potential but also for access to a highly skilled local workforce.
“This investment strengthens our ability to support future medical breakthroughs while building a long-term partnership with North Carolina,” said CEO Robert Michael.
The project is backed by a performance-based incentive package, with the state offering up to $19.3 million in reimbursements over 12 years, conditional on job creation and investment targets. An additional $6.4 million could be allocated to infrastructure development in rural areas.
AbbVie estimates the campus will generate up to $8 billion in economic impact for the state.
This announcement is part of a broader $100 billion commitment by AbbVie to US-based R&D and manufacturing over the next decade. It also reflects a wider industry trend, with pharmaceutical companies accelerating domestic investments amid geopolitical tensions and evolving trade dynamics.
Recent examples include CSL Behring’s $1.5 billion facility in Illinois and major investments by Johnson & Johnson and Eli Lilly in Pennsylvania, reinforcing a clear shift toward reshoring and supply chain resilience.
